GLENMARK PHARMA
IDMA best biotech NEW MOLECULAR ENTITY patent award to Glenmark
YEAR 2012-2013 YEAR in Mumbai India
PATENT US 8236315
GLENMARK PHARMACEUTICALS, S.A., SWITZERLAND
INVENTORS
|
Elias Lazarides, Catherine Woods, Xiaomin Fan, Samuel Hou, Harald Mottl, Stanislas Blein, Martin BertschingerALSO PUBLISHED ASCA2712221A1, CN101932606A,EP2245069A1, US20090232804,WO2009093138A1
| Publication number |
US8236315 B2 |
| Publication type |
Grant |
| Application number |
US 12/358,682 |
| Publication date |
7 Aug 2012 |
| Filing date |
23 Jan 2009 |
| Priority date |
23 Jan 2008 |
|
USPTO, USPTO Assignment, Espacenet, US 8236315
The present disclosure relates generally to humanized antibodies or binding fragments thereof specific for human von Willebrand factor (vWF), methods for their preparation and use, including methods for treating vWF mediated diseases or disorders. The humanized antibodies or binding fragments thereof specific for human vWF may comprise complementarity determining regions (CDRs) from a non-human antibody (e.g., mouse CDRs) and human framework regions.
The present disclosure provides a humanized antibody or binding fragment thereof specific for vWF that comprises a heavy chain variable region sequence as set forth in SEQ ID NO: 19 and a light chain variable region sequence as set forth in SEQ ID NO: 28 ……….. CONT
MR GLEN SALDANHA
MD , CEO GLENMARK
102-B Poonam Chambers, Dr A B Road, Worli, Mumbai 400 018, INDIA
Tel : +91 – 22 – 24944625 / 24974308. Fax : ++91 – 22 – 24957023
email: ppr@idmaindia.com website : www.idma-assn.org
.
